In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival ...
Qurient announced the first patient dosed in a Phase 2 study of mocaciclib (Q901) for CDK4/6 inhibitor-resistant HR+ breast ...
MedPage Today on MSN
Abemaciclib poised to be new standard of care in aggressive liposarcoma
Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SA ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first ...
Eli Lilly's Verzenio could offer the first targeted therapy for dedifferentiated liposarcoma (DDLPS), an aggressive cancer that usually needs to be treated with chemotherapy, according to the results ...
In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
Zacks Investment Research on MSN
FDA extends review time for AZN's camizestrant combo in breast cancer
AstraZeneca AZN announced that the FDA will extend the Prescription Drug User Fee Act (PDUFA) date for reviewing the new drug ...
Sara M. Tolaney, MD, MPH: Given the data that are available for the use of CDK4 and CDK6 inhibitors in metastatic hormone receptor—positive disease, I think the class of agents is really something ...
Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, ...
Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results